immunoforge Venture Capital
4 known investors
ImmunoForge is a South Korean drug development company that builds a pipeline of therapeutics based on its ELP (elastin-like polypeptide) half-life extension platform and a blood-brain-barrier shuttle platform (LMT15). Its programs include candidates for chronic myelogenous leukemia (KF1601) and Duchenne muscular dystrophy cardiomyopathy (Pemziviptadil).
Also known as ImmunoForge · ImmunoForge Co. Ltd. · 이뮤노포지
Founders & leadership
Investors · 4
Company profile
researched Aug 2026ImmunoForge Co., Ltd. (이뮤노포지㈜) is a South Korean pharmaceutical research and development company that designs therapeutics using long-acting technology. Its work is organized around two proprietary platforms: an ELP platform used for half-life extension of biologic drugs, and the LMT15 platform, a blood-brain-barrier (BBB) shuttle intended to enable delivery of therapeutics into the central nervous system.
The company maintains a multi-asset pipeline built on these platforms, with disclosed programs including Froniglutide, Pemziviptadil, KF1601, PF1802, PF1803, PF1805, PF1806 and PF1807, alongside government-funded research projects. Regulatory milestones announced by the company include Korean MFDS clearance of a Phase 1 IND for KF1601, a chronic myelogenous leukemia candidate, and U.S. FDA clearance of a Phase 2 IND for Pemziviptadil in Duchenne muscular dystrophy cardiomyopathy. The company is led by co-CEOs Sungmin Ahn and Giho Jang.
Business model
Development of proprietary drug candidates on in-house long-acting and BBB-shuttle platforms, with out-licensing (technology transfer) of platform-enabled assets to domestic and overseas pharmaceutical companies pursued as a route to revenue.
Traction
Regulatory progress includes Korean MFDS approval of a Phase 1 IND for KF1601 in chronic myelogenous leukemia and U.S. FDA approval of a Phase 2 IND for Pemziviptadil in Duchenne muscular dystrophy cardiomyopathy, plus recognition in pitching competitions including first place at a Novo Nordisk 2026 event.
Latest developments
The company reported being selected first at a Novo Nordisk 2026 pitching event held to identify promising Korean companies, and separately reported a first-place finish in a global pitching event for its drug delivery technology. It attended Bio-Europe Spring 2026 for LMT15 licensing partnering. Corporate notices posted in September and October 2025 announced new share issuances of registered redeemable convertible preferred stock and a debt-to-equity conversion share issuance, and a notice convening the 9th annual general shareholders' meeting was issued by co-CEOs Sungmin Ahn and Giho Jang. Co-CEO Giho Jang stated the company was conducting multiple licensing-out discussions for its long-acting platform and was carrying out a Series C financing, which he said was targeted to close in March.
▸Full profile — technology, go-to-market, geography
Technology
Two platform technologies underpin the pipeline: an ELP (elastin-like polypeptide) platform applied to extend the circulating half-life of drug candidates, and LMT15, a blood-brain-barrier shuttle platform used for central nervous system delivery and offered for global licensing partnering.
Go-to-market
Business development is conducted through partnering at international industry conferences and licensing negotiations; the company reported attending Bio-Europe Spring 2026 in Lisbon, Portugal (23-25) to pursue global licensing discussions for LMT15 with pharmaceutical companies and investors, and stated goals of signing technology-transfer agreements with two domestic companies and at least one overseas company.
Global and Korean pharmaceutical companies as licensing partners, and ultimately patients with conditions addressed by the pipeline, including chronic myelogenous leukemia and Duchenne muscular dystrophy cardiomyopathy.
Geography
Headquartered in Seoul, South Korea, with offices and an affiliated corporate research institute at Ace Hansol Tower, 58 Gasan Digital 1-ro, Geumcheon-gu, Seoul (08591); the company also lists a United States branch office.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 6
launches, deals, and filingsThe company attended Bio-Europe Spring 2026 in Lisbon, Portugal on the 23rd-25th to conduct global licensing partnering for its LMT15 blood-brain-barrier shuttle platform with pharmaceutical companies and investors.
ImmunoForge was selected first at a Novo Nordisk pitching event held to identify promising Korean companies and explore investment opportunities; the company also reported a first-place finish in a global pitching event for its drug delivery technology.
ImmunoForge announced that Korea's Ministry of Food and Drug Safety approved a Phase 1 IND for KF1601, a candidate under development for chronic myelogenous leukemia.
ImmunoForge announced U.S. FDA approval of a Phase 2 IND for Pemziviptadil, developed for Duchenne muscular dystrophy cardiomyopathy.
A board resolution authorized issuance of registered redeemable convertible preferred shares, publicly noticed under Korean Commercial Act articles 416, 344 and 418.
Corporate notices announced board resolutions for issuance of registered redeemable convertible preferred shares and for a share issuance arising from a debt-to-equity conversion.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- immunoforge Venture Capitalimmunoforge.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does immunoforge Venture Capital do?
- South Korean drug developer building long-acting therapeutics on its ELP half-life extension and LMT15 BBB shuttle platforms.
- Who are immunoforge Venture Capital's investors?
- immunoforge Venture Capital's investors include Aju IB Invesment Corporation, IMM Investment Japan, Kiwoom Investment, We Ventures.